Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury (EVOLVE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test their plasma for a biomarker called NGAL and compare the NGAL levels to their creatinine levels. We hypothesize that NGAL is an earlier marker for kidney injury than creatinine.
| Condition |
|---|
|
Kidney Failure, Acute |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | EValuation Of NGAL in Early and eVolving Acute kidnEy Injury |
Blood Samples (3 10ml, 7 5ml) at ten timepoints over 5 days.
| Enrollment: | 355 |
| Study Start Date: | February 2007 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
High Risk population for developing AKI during/after CABG surgery.
|
|
2
Medium Risk population for developing AKI during/after CABG surgery.
|
Detailed Description:
Approximately 350 adults scheduled to undergo cardiac surgery involving the use of cardiopulmonary bypass will be enrolled. Blood samples will be obtained from all patients in the study for future measurement of both plasma NGAL and plasma creatinine levels in the same sample at each of nine time points.
Blood samples for later assessment using the Triage NGAL Test will be processed to plasma at the clinical site, frozen and shipped to Biosite for storage. Testing with the Triage NGAL Test will be conducted at Biosite by trained laboratory personnel. The results of these assessments will be blinded to the medical team during the study and will not impact the medical management of the patient.
The medical team caring for each study patient should obtain clinical laboratory tests per their usual post-operative routine and manage the patient accordingly. Any serum creatinine measurements obtained by the site as part of this routine care both pre-operatively and through Day 10 post-operatively will be recorded as well as any additional post-operative renal insults, the development of oliguria, the need for a nephrology consultation, initiation of dialysis and mortality will also be recorded through Day 10.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients undergoing CABG Surgery that are thought to have a risk of developing AKI during/after surgery.
4.2.1 Inclusion Criteria
- Male or female scheduled for cardiovascular surgery (other than cardiac transplant) requiring cardiopulmonary bypass
- 18 years of age or older
i. The first approximately 150 to200 patients enrolled must have:
• A Prediction of Acute Renal Failure Score ≥ 5 (see Reference 18 and Appendix B)
ii. The subsequent patients enrolled must have one or more of the following risk factors for post-bypass renal injury:
- Age > 70;
- Pre-operative creatinine > 1.4 mg/dL;
- NYHA Class 3 or 4 heart failure or left ventricular ejection fraction < 35%;
- Insulin-dependent diabetes mellitus;
- Undergoing cardiac valve surgery;
- History of previous cardiac surgery.
Exclusion Criteria:
- Age < 18 years
- Inability to obtain Informed Consent from patient or representative
- Prisoners or other institutionalized or vulnerable individuals
- Participation in an interventional clinical study within the previous 30 days
- History of previous renal transplantation
- Stage 5 chronic kidney disease (estimated GRF<15 mL/min/1.73m2) (See Appendix C)
- Known or suspected ongoing pre-operative acute renal failure due to any cause, including pre-renal, intrinsic renal or post-renal (obstructive) etiologies (as evidenced by increasing serum creatinines or oliguria pre-operatively)
- Already receiving dialysis, in imminent need of dialysis or considered highly likely to need dialysis in the immediate post-operative period for fluid management
- Any known or suspected renal ischemic insult(such as cardiac arrest)or nephrotoxic insult(other than intravascular contrast procedure) during the 48 hours prior to surgery
- Known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV)infection, hepatitis B virus (HBV) infection or other infectious hepatitis
- Pre-operative hematocrit <25%, recent blood transfusions have been administered to maintain hematocrit >25% or any other contraindication to obtaining the study-specified blood samples
- Undergoing cardiac transplantation
Contacts and Locations| United States, Colorado | |
| St. Anthony's Central Hospital | |
| Denver, Colorado, United States | |
| United States, District of Columbia | |
| George Washington University | |
| Washington, District of Columbia, United States | |
| United States, Maine | |
| Maine Medical Center | |
| Portland, Maine, United States | |
| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States | |
| United States, New York | |
| St. Peters Healthcare | |
| Albany, New York, United States | |
| New York Methodist | |
| Brooklyn, New York, United States | |
| United States, Ohio | |
| Cleveland Clinic Foundation | |
| Cleveland, Ohio, United States | |
| United States, Pennsylvania | |
| University of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States | |
| United States, Texas | |
| University of Texas, Houston | |
| Houston, Texas, United States | |
| Canada, British Columbia | |
| University of British Columbia | |
| Vancouver, British Columbia, Canada | |
| Principal Investigator: | Emil Paganini, MD | The Cleveland Clinic |
More Information
No publications provided
| Responsible Party: | Kyle Fortner, CRA, Biosite, Incorporated a subsidiary of Inverness Medical Innovations |
| ClinicalTrials.gov Identifier: | NCT00445809 History of Changes |
| Other Study ID Numbers: | BSTE-0401 |
| Study First Received: | February 15, 2007 |
| Last Updated: | August 3, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Biosite:
|
Kidney Renal Cardiac Surgery with bypass Cardiovascular surgery with cardiopulmonary bypass |
Additional relevant MeSH terms:
|
Acute Kidney Injury Renal Insufficiency Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013